The mammalian transient protein expression market is estimated to reach USD 762.34 million in 2024. It is estimated that revenue will increase at a CAGR of 5.5% between 2024 and 2034. The market is anticipated to reach USD 1,303.55 million by 2034.
Mammalian Transient Protein Expression is a technique that is being used to produce recombinant proteins in mammalian cells. It is a host system for producing mammalian proteins that have native structure and activity. This host system are commonly used for the production of antibodies and therapeutic proteins, and they can also be used for the production of proteins that are used by humans in functional cell based assays.
The mammalian transient protein expression system enable the flexible and rapid production of proteins and are ideal for generating large amounts of proteins within short period of time.
The flexibility of mammalian transient protein expression system to accommodate wide range of protein targets and the advantage of offering post-translational modifications (PTMs) hat are essential for proper protein folding, stability, and biological activity majorly contributes to the growth of the market.
Mammalian Transient Protein Expression Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 721.29 million |
| Estimated Size, 2024 | USD 762.34 million |
| Projected Size, 2034 | USD 1,303.55 million |
| Value-based CAGR (2024 to 2034) | 5.5% |
Transient gene expression (TGE) in mammalian cells is becoming one of the routine process in the expression of recombinant protein in cell lines such as human embryonic kidney 293 and Chinese hamster ovary cells owing to the rapidly increasing need for recombinant proteins.
In addition to this, its ability to enable post translational modification such as glycosylation and phosphorylation which are essential for proper functioning of protein. This post translational modification capabilities aid in the production of full length recombinant antibodies.
Mammalian transient protein expression also has ability to adapt different cell culture conditions which facilitates large scale production of proteins. Moreover, the low risk of immunogenicity associated with the mammalian system anticipates its further growing demand in the market.
Mammalian transient protein expression has an important role in the research study as it has ability to efficiently study the effects of different proteins and cellular process in short period of time.
Use of transient protein in mammalian cells allows for quick production of proteins, which accelerates the early stages of drug development and allows for faster screening of potential therapeutic candidates. These mammalian cells also optimizes the production conditions in order to meet the specific needs which facilitates the development of new protein based drugs.
Therefore, the increasing research studies on proteomics and biologics and the increasing application of mammalian transient protein expressions in the process of drug discovery surges its demand in the pharmaceutical industry.
Explore FMI!
Book a free demo
The table below offers a comparative analysis of the Compound Annual Growth Rate (CAGR) fluctuations for the global mammalian transient protein expression market between the base year (2023) and the current year (2024) over six months.
This examination uncovers significant changes in market performance and highlights trends in revenue generation, giving stakeholders valuable insights into the market’s growth trajectory throughout the year. The first half (H1) encompasses January through June, while the second half (H2) covers July through December.
The first half (H1) is the period from January to June, and the second half (H2) is July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 6.2%, followed by a slightly lower growth rate of 5.9% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 6.2% (2023 to 2033) |
| H2 | 5.9% (2023 to 2033) |
| H1 | 5.5% (2024 to 2034) |
| H2 | 5.0% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 5.5% in the first half and remain relatively moderate at 5.0% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Growing Investment in R&D of Biopharmaceutical Products Influence the Market
Mammalian systems of transient expression have certain advantages that turn them into a must for research and bioproduction. They are able to accelerate and flexibly produce proteins required in earlier stages of research, they also have ability to screen potential drug candidates and optimize therapeutic proteins.
Moreover, its further use for the production of complex proteins, monoclonal antibodies, and therapeutic proteins that require correct folding processes and post-translational modifications like glycosylation further contributes to its growing demand in the biopharmaceutical industry.
Cell line engineering, technologies for transfection, and culture conditions have continued to improve the transient expression systems in mammals which has improved their efficiency, yield, application spectrum and their relative cost-effectiveness that is essential for the production of moderate protein quantity.
Therefore, surge in investment in research and development of biopharmaceuticals all across the globe, growing potential of mammalian transient protein expression to meet stringent requirements on protein quality and its ability to develop novel therapeutics in fast times significantly contributes to its increasing demand in the biopharmaceutical industry.
Increase in investment for research and development of biopharmaceuticals, is significantly contributing to the growing demand of mammalian transient protein expression. In addition, its growing potential to meet up with the stringent requirements on protein quality, regulatory compliance, and fast timelines of production in the development of novel therapeutics further anticipates its market growth.
Growing demand for Market from Contract Research Organizations
Mammalian Transient Protein Expression are becoming increasing favorite among contract research organizations due to their ability meet several challenges in the drug discovery. They assists in rapid and flexible production of proteins that are of central importance in early-stage drug discovery and validation processes.
This flexibility of transient proteins is invariably of great value for the different needs of the pharmaceutical and biotechnology industries in terms of the production of therapeutic proteins and monoclonal antibodies, protein characterization, and assay development.
The demand for mammalian transient protein expression is also growing among CROs due to cost effectiveness as compared to other cell lines development which requires a huge upfront investment. This factor assists CROs to offer their products and services to the market at a more competitive price by maintaining their profitability.
In addition to this, improving technology in transient protein expression also assists contract research organizations work at greater efficiency and scalability which ultimately grow their production capabilities. These factors aid contract research organizations to timely apt for protein production services and support acceleration pace of innovation in biopharmaceutical industry.
Advancements in Gene Expression Platforms Anticipates the Market Growth
Gene expression platforms have contributed immensely for improvements in mammalian transient protein expression systems and the production of proteins. Improved vector design by incorporation of potent promoters, enhancers, and regulatory elements increases the efficiency of cell uptake through transfection and contributes to the improved protein yield.
These vectors are specific in certain mammalian cell lines that facilitate the production of proteins with desired folding and post-translational modifications that are necessary for biological activity.
The entry of innovative methods of transfection, such as lipid-based reagents and electroporation, has tremendously improved the delivery of expression to cells. This has resulted into increased transfection efficiency. At the same time, the growing advancements on cell line engineering has further enhanced the efficiency of host cells that are now being used for the production of complex proteins at industrial scales.
Moreover, improvements in culture conditions and media formulations have optimized the kinetics of cell growth and protein production, which further enhances the productivity without any loss to protein quality. Therefore, the growing automation and high-throughput screening technologies, has given a boost to the identification of optimal expression conditions on the one hand and have also increased the throughput for protein characterization.
These developments have, therefore, not only extended the abilities of TPE systems but have also contributed to the general use of these systems in biopharmaceutical research, drug development, and biotechnology applications.
Surging Number of Pharmaceutical Production Facilities in Emerging Nations Demonstrates Growth Opportunities
Growing number of pharmaceutical production facilities in emerging nations is playing an essential role in the growth of the mammalian transient protein expression (TPE) market. These facilities not only play a vital role but also assist in meeting the largely growing global demand for biologic drugs in the shape of monoclonal antibodies, vaccines, and therapeutic proteins.
The lower operational cost, with access to skilled labor, becomes the attractive factors for pharmaceutical firms to establish hubs for biologics in such emerging markets.
Moreover, regulatory evolution in emerging countries has also facilitated the fast-track approval of biologic drugs from mammalian TPE. Furthermore, the growing partnerships and technology transfer agreements by global pharmaceutical companies with local parties in emerging markets aids and abets the entry of mammalian TPE technologies. Such alliances fast-track the deployment of biologic production capability at a higher speed.
Such capacity growth in the pharmaceuticals manufacturing industry within emerging countries contributes to the growth of global biologics drugs which is one of the major factor for the growth of mammalian transient protein expression market.
The mammalian transient protein expression industry recorded a CAGR of 5.5% between 2019 and 2023. According to the industry, mammalian transient protein expressions generated USD 721.3 million in 2023, up from USD 614.3 million in 2019.
The commercial demand for TPE has significantly increased with the biologics revolution in the manufacture of complex therapeutic proteins. These biologics includes monoclonal antibodies and cytokines, which have grown more favorably in the market due to their specificity and effectiveness in the treatment of various diseases.
Advancements in genetic engineering holds a central place in manipulation of mammalian cells which allows direct expression of proteins that are of interests to the manufacturers in the short term.
This improvement in technology has significantly proliferated applications of transient protein expression (TPE) across a wide range of the biologics space. These factors have contributed to the growing interest of the pharmaceutical companies in developing their operation efficiently and at scale.
Moreover, the products developed using mammalian transient protein expression have received regulatory approval from bodies such as the FDA and EMA, which allows a clear route for the commercialization of such biologic drugs.
Moreover, the growing collaboration and rising investment in the development of cell culture techniques, expression vector design, and media formulations are few of the other factors that are contributing to the growth of the market. These investments are majorly aimed to improve the efficiency of the TPE process at reduced cost which is enabling it to become one of the most prominent technique for biologic production.
These factors all together are propelling the development of mammalian transient protein expression (TPE) technologies in the biopharmaceutical industry.
Companies in the Tier 1 sector account for 51.2% of the global market, ranking them as the dominant players in the industry. Tier 1 players offer a wide range of products compared to other emerging players, have an established industry presence, offer continuous innovation, and have a significant influence in the field.
A strong brand recognition and a loyal customer base provide them with a competitive advantage. Moreover, their strong financial resources enables them to enhance their research and development efforts and expand into new markets. Prominent companies within Tier 1 include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc, and Agilent Technologies, Inc.
Tier 2 players dominate the industry with a 37.1% market share. Tier 2 firms have a strong focus on a specific technologies and a substantial presence in the industry, but they have less influence than Tier 1 firms. The players are more competitive when it comes to pricing and target niche markets.
They constantly focus on introducing new products and services. Tier 2 companies include Lonza, FUJIFILM Wako Pure Chemical Corporation, Promega Corporation, Qiagen, Sartorius AG, Takara Bio, Mirus Bio and Creative BioMart
Tier 3 companies many of the times are limited to the local markets due to their limited production capabilities and geographical presence. Those in Tier 3 focus primarily on serving a smaller number of pharmaceutical clients. Few of the prominent players Creative Biolabs, GeneCopoeia, Inc., HiMedia Laboratories
An analysis of the mammalian transient protein expression industry is provided in various countries. Several regions throughout the world are examined, including Asia Pacific, North America, and Europe. USA is forecast to remain the leader with a 6.9% CAGR through 2034. Whereas, South Korea is anticipated to grow at a CAGR of 6.8% through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 6.9% |
| Canada | 4.4% |
| United Kingdom | 5.0% |
| Germany | 6.7% |
| India | 5.8% |
| China | 5.4% |
| South Korea | 6.8% |
Surge in demand for biological drugs like monoclonal antibodies and therapeutic proteins in the country, accelerating the interest in TPE technology. Biologics are majorly preferential and recommended drugs due to their specificity and efficiency in treating complex diseases. In addition, growing trend of preference towards personalized medicine anticipates the growth of the mammalian transient protein expression market in the country.
Growing technological advancements in genetic engineering, cell culture techniques, and expression vector design that has significantly helped in increasing the efficiency and scalability of TPE further augments the market growth. Moreover, association of lower production costs, with reduced timescales, makes it an attractive proposition for pharmaceutical companies those are willing to bring biologic therapies to market.
Further, the presence of well-established pharmaceutical R&D infrastructure in the USA those are willing to make crucial investments in biotechnology act as paving stones for the market of TPE.
These factors act as a very conducive atmosphere for the growth of the mammalian transient protein expression market in the USA and, as a matter of fact, makes it the cornerstone for drug development and production for biologics.
The investment made by private investors and the support extended by the government provides a congenial environment for proactive development of this industry in South Korea. Furthermore, availability of technological advancement in genetic engineering, cell culture techniques, and bioprocessing units strengthens the capabilities of South Korea in this industry.
These strong capabilities of the pharmaceutical industries of South Korea contribute to increased adoption and optimization of TPE for the efficient production of biologic drugs, including monoclonal antibodies and therapeutic proteins.
Besides, industries in South Korea, being oriented toward close cooperation with academia and research institutions, allows young talent to participate in their R&D process, thus keeping them at the leading edge of these fast-growing, competitive markets.
These are just a few of the factors that have helped propel South Korea into one of the top spots for developing and manufacturing biologic drugs via mammalian transient protein expression.
Germany has a well-built biotechnology sector with massive research infrastructure, and an educated and skilled work force. The government also extends their support by providing funding to their biopharmaceutical innovation. Such is the environment that offers accelerated innovation in genetic engineering, cell culture techniques, and expression vector design, covering improvements in TPE process efficiency and scalability.
Strong collaboration between academia, research institutions, and industry players further drives innovation in TPE technology, thereby facilitating the development of new biologic therapies and improvement of existing manufacturing techniques for products.
Increasing healthcare needs, coupled with preference for targeted therapies, and increase in market demand for biologics in Germany augments the growth of the market in the country.
Moreover, presence of highly skilled workforce in the biotech and pharmaceuticals supports the effective implementation and optimization of transient protein expression systems. Therefore, growing investment in R&D and increasing demand for high qualitative biologic drugs with affordable prices propels the growth of the market in the country.
A description of the leading segments in the industry is provided in this section. The expression vector segment held 28.4% of the value share in 2023. Based on the end user, contract research organization held 45.7% of the market in 2023.
| Application | Expression vectors |
|---|---|
| Value Share (2024) | 28.5% |
Expression vectors plays an important role in the mammalian transient protein expression market. They are essential for the production of various proteins in mammalian cells. They act as a molecular vehicles that are designed to carry and deliver genes that are essential for the coding of desired proteins into host cells.
This has been mainly caused by the versatility in accommodating different protein targets and regulatory sequences, especially in the control of gene expression levels and protein production.
Their scalability from benchtop research to large-scale biomanufacturing makes them one of the consistent protein expression with high yields that are essential for addressing biopharmaceutical needs. Commercially available expression vectors have an optimized format for the specific mammalian cell lines and production requirements, contributing to easy research development in academia and industry alike.
In general, expression vectors form a core technology in the TPE market, underscoring the developments in biotechnology, pharmaceutical development, and the production of therapeutic proteins hence, they retain the largest share in the landscape of mammalian transient protein expression.
| End User | Contract Research Organization |
|---|---|
| Value Share (2024) | 45.6% |
Contract Research Organizations hold a predominant share of the mammalian transient protein expression market due to their core competencies and a central role that falls within the biopharmaceutical research and development process.
CROs are fully equipped with ultramodern infrastructure, cutting-edge technologies, and well-trained experienced staff committed to the optimization of TPE processes. Preferential shift of established manufacturers to get their products manufactured from CROs owing to its cost efficient benefits and reduced operational charges has majorly aided CROs to hold highest share of the market.
Moreover, CROs ensure the meeting of regulatory requirements and compliance, meaning that the preclinical and clinical developments are followed up in a line. Quality assurance and documentation expertise gives support to regulatory submissions, adding credibility to research results. Thus, these factors has significantly aided CROs to highest share of these growing market.
Competitor players such as Thermo Fisher Scientific and Merck KgaA holds the majority of the shares of the market as they are known for their advanced technologies in cell line development, vector systems, and bioprocessing.
Moreover, Strategic partnerships, acquisitions, and global market reach are key strategies that are being adopted by the other key players operating in the market.
Diversification of existing players into providing related services such as stable cell line development and contract manufacturing further enhances competitiveness. Whereas, growing innovation with ongoing advancements aimed at improving protein yield, scalability, and meeting the evolving demands of biopharmaceutical research and development further anticipates the growth of the market in near future.
Recent Industry Developments in the Mammalian Transient Protein Expression Market
Mammalian transient protein expression are expected to increase at a CAGR of 5.5% between 2024 and 2034.
The dental clinics segment is expected to occupy a 28.5% market share in 2024.
The market for mammalian transient protein expressions is expected to reach USD 1,303.5 million by 2034.
The United States is forecast to see a CAGR of 6.9% during the assessment period.
The key players in the mammalian transient protein expression industry include Thermofisher Scientific, Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc, and Agilent Technologies, Inc.
In terms of product, the industry is segregated into instruments, expression vectors, cell lines (Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK 293) cells and others cell lines) and reagents and consumables
In terms of Application, the industry is segregated into bio-production (antibody production and therapeutic protein production), functional cell-based assays, academic research and others
In terms of end user, the industry is segmented into biopharmaceutical companies, contract research organizations and academic & research institutes
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East, and Africa have been covered in the report.
Mammalian Transient Protein Expression Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
